Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Adv Exp Med Biol ; 1049: 255-273, 2018.
Article in English | MEDLINE | ID: mdl-29427108

ABSTRACT

Machado-Joseph disease (MJD) also known as Spinocerebellar ataxia type 3, is a hereditary neurodegenerative disease associated with severe clinical manifestations and premature death. Although rare, it is the most common autosomal dominant spinocerebellar ataxia worldwide and has a distinct geographic distribution, reaching peak prevalence in certain regions of Brazil, Portugal and China. Due to its clinical heterogeneity, it was initially described as several different entities and as had many designations over the last decades. An accurate diagnosis become possible in 1994, after the identification of the MJD1 gene. Among its wide clinical spectrum, progressive cerebellar ataxia is normally present. Other symptoms include pyramidal syndrome, peripheral neuropathy, oculomotor abnormalities, extrapyramidal signs and sleep disorders. On the basis of the presence/absence of important extra-pyramidal signs, and the presence/absence of peripheral signs, five clinical types have been defined. Neuroimaging studies like MRI, DTI and MRS, can be useful as they can characterize structural and functional differences in specific subgroups of patients with MJD. There is no effective treatment for MJD. Symptomatic therapies are used to relieve some of the clinical symptoms and physiotherapy is also helpful in improving quality of live. Several clinical trials have been carried out using different molecules like sulfamethoxazole-trimethoprim, varenicline and lithium carbonate, but the results of these trials were negative or showed little benefit. Future studies sufficiently powered and adequately designed are warranted.


Subject(s)
Ataxin-3 , Machado-Joseph Disease , Neuroimaging , Repressor Proteins , Ataxin-3/genetics , Ataxin-3/metabolism , Clinical Trials as Topic , Humans , Machado-Joseph Disease/diagnostic imaging , Machado-Joseph Disease/drug therapy , Machado-Joseph Disease/genetics , Machado-Joseph Disease/metabolism , Repressor Proteins/genetics , Repressor Proteins/metabolism
2.
Sci Rep ; 6: 28220, 2016 06 22.
Article in English | MEDLINE | ID: mdl-27328712

ABSTRACT

Machado Joseph Disease (MJD) is the most frequent autosomal dominantly inherited cerebellar ataxia caused by the over-repetition of a CAG trinucleotide in the ATXN3 gene. This expansion translates into a polyglutamine tract within the ataxin-3 protein that confers a toxic gain-of-function to the mutant protein ataxin-3, contributing to protein misfolding and intracellular accumulation of aggregates and neuronal degeneration. Autophagy impairment has been shown to be one of the mechanisms that contribute for the MJD phenotype. Here we investigated whether this phenotype was present in patient-derived fibroblasts, a common somatic cell type used in the derivation of induced pluripotent stem cells and subsequent differentiation into neurons, for in vitro disease modeling. We generated and studied adult dermal fibroblasts from 5 MJD patients and 4 healthy individuals and we found that early passage MJD fibroblasts exhibited autophagy impairment with an underlying mechanism of decreased autophagosome production. The overexpression of beclin-1 on MJD fibroblasts reverted partially autophagy impairment by increasing the autophagic flux but failed to increase the levels of autophagosome production. Overall, our results provide a well-characterized MJD fibroblast resource for neurodegenerative disease research and contribute for the understanding of mutant ataxin-3 biology and its molecular consequences.


Subject(s)
Autophagy , Fibroblasts/metabolism , Machado-Joseph Disease/pathology , Ataxin-3/genetics , Ataxin-3/metabolism , Autophagosomes/metabolism , Beclin-1/genetics , Beclin-1/metabolism , Cells, Cultured , DNA/isolation & purification , DNA/metabolism , Fibroblasts/cytology , Genetic Vectors/genetics , Genetic Vectors/metabolism , Genotype , Humans , Karyotype , Machado-Joseph Disease/genetics , Machado-Joseph Disease/metabolism , Microtubule-Associated Proteins/metabolism , Sequestosome-1 Protein/metabolism
4.
Neuropsychologia ; 47(5): 1269-73, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19428390

ABSTRACT

Implicit contextual learning refers to the ability to memorize contextual information from our environment. This contextual information can then be used to guide our attention to a specific location. Although the medial temporal lobe is important for this type of learning, the basal ganglia might also be involved considering its role in many implicit learning processes. In order to understand the role of the basal ganglia in this top-down process, a group of non-demented early-stage Parkinson's patients were tested with a contextual cueing task. In this visual search task, subjects have to quickly locate a target among a number of distractors. To test implicit contextual learning, some of the configurations are repeated during the experiment, resulting in faster responses. A significant interaction effect was found between Group and Configuration, indicating that the control subjects responded faster when the spatial context was repeated, whereas Parkinson's patients failed to do so. These results, showing that the contextual cueing effect was significantly different for the patients than for the controls, suggest an important role for the basal ganglia in implicit contextual learning, thus extending previous findings of medial temporal lobe involvement. The basal ganglia are therefore not only involved in implicit motor learning, but may also have a role in purely visual implicit learning.


Subject(s)
Basal Ganglia/physiopathology , Learning/physiology , Memory/physiology , Parkinson Disease/physiopathology , Case-Control Studies , Female , Field Dependence-Independence , Humans , Male , Middle Aged , Reaction Time
SELECTION OF CITATIONS
SEARCH DETAIL
...